Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL946654 | 0.98 | SMN1; SMN2 (0.91) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Bromide SCHEMBL11793837 | 0.98 | SMN1; SMN2 (0.91) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| SCHEMBL1858113 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| SCHEMBL472290 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL9870336 | 0.96 | CYP1A2 (0.96) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL11544283 | 0.96 | CYP1A2 (0.96) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1127792 | 0.96 | CYP1A2 (0.96) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Methane SCHEMBL11633126 | 0.94 | CYP1A2 (0.92) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| SCHEMBL1856267 | 0.93 | CYP1A2 (0.83) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| SCHEMBL9151071 | 0.91 | CYP1A2 (0.80) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-09-04 | — | — | US | claimed |
| US-11424006-B2 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | PSOMAGEN, INC. (US) | 2022-08-23 | — | — | US | claimed |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MACROGEN INC. (KR) | 2021-05-06 | — | — | US | claimed |
| CN-111163761-A | Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide | 普梭梅根公司 | 2020-05-15 | — | — | CN | claimed |
| US-20190050525-A1 | RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES | PSOMAGEN, INC. | 2019-02-14 | — | — | US | claimed |
| US-20100113450-A1 | Agent for Preventing and Alleviating Wrinkles | SHISEIDO COMPANY LTD. (JP) | 2010-05-06 | — | — | US | claimed |
| EP-2123253-A1 | WRINKLING-PREVENTING AND -MODIFYING AGENT | Shiseido Company, Ltd. (JP) | 2009-11-25 | — | — | EP | claimed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | claimed |
| US-20260078099-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | SUZHOU HEALIRNA BIOTECHNOLOGY CO., LTD. (CN) | 2026-03-19 | — | — | US | disclosed |
| EP-4650349-A1 | COMPOUND, PREPARATION METHOD, AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITION THEREOF | Suzhou Healirna Biotechnology Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250213493-A1 | NANOMATERIALS COMPRISING TRIOLS | BEAM THERAPEUTICS INC. | 2025-07-03 | — | — | US | disclosed |
| US-12296053-B2 | Nanomaterials comprising triols | BEAM THERAPEUTICS INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4540222-A1 | NANOMATERIALS COMPRISING TRIOLS | Beam Therapeutics Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119698406-A | Nanomaterials comprising triols | 比姆医疗股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-4025630-A | Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication | ABBOTT LABORATORIES (US) | 1977-05-24 | — | — | US | disclosed |
| US-4020163-A | Use of heterocyclic esters of 5H-[1]benzopyrano [3,4-b]pyridines as analgesics | SHARPS ASSOCIATES (US) | 1977-04-26 | — | — | US | disclosed |
| US-3991194-A | Heterocyclic esters of benzopyranopyridines | SHARPS ASSOCIATES (US) | 1976-11-09 | — | — | US | disclosed |
| US-3972880-A | TRANQUILIZER | SHARPS ASSOCIATES (US) | 1976-08-03 | — | — | US | disclosed |
| US-3960871-A | ANTIDEPRESSANT, ANALGESICS, ANTICONVULSANT ANTI-ANXIETY ACTIVITY | SHARPS ASSOCIATES (US) | 1976-06-01 | — | — | US | disclosed |
| US-3941782-A | Heterocyclic esters of benzopyrans | SHARPS ASSOCIATES (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11424006-B2 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | PNMT, MAOA, HNMT | SMN1; SMN2 2842/4885CYP1A2 116/4885MAPK1 2712/4885 |
| US-20260078099-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | SGMS1, LDLR, NR5A1 | SMN1; SMN2 1014/4885CYP1A2 235/4885MAPK1 1432/4885 |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MAOA, PNMT, HNMT | SMN1; SMN2 2279/4885CYP1A2 69/4885MAPK1 1829/4885 |
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | SMN1; SMN2 3944/4885CYP1A2 2641/4885MAPK1 4178/4885 |
| US-20100113450-A1 | Agent for Preventing and Alleviating Wrinkles | GABRB1, GABRB2, GABBR1 | SMN1; SMN2 1147/4885CYP1A2 706/4885MAPK1 2400/4885 |
| US-12296053-B2 | Nanomaterials comprising triols | PNPLA2, LIPA, PHOSPHO1 | SMN1; SMN2 760/4885CYP1A2 3545/4885MAPK1 4328/4885 |
| US-20250213493-A1 | NANOMATERIALS COMPRISING TRIOLS | PNPLA2, LIPA, PHOSPHO1 | SMN1; SMN2 760/4885CYP1A2 3545/4885MAPK1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.